Stock Taper 
AKTS
$27.05
▲ UP 1.50% (0.40)
KEY STATISTICS
Market Cap$1.44 B
52w High$34.19
52w Low$14.72
Dividend Yield—
Frequency—
P/E-1.46
Volume159.25K
Shares Out.53.40M
COMPANY
LEADERSHIP
CHIEF EXECUTIVE
Matthew Roden
ABOUT
SECTOR
Healthcare
WENT PUBLIC
January 9, 2026
METHOD OF GOING PUBLIC
IPO
FULL TIME EMPLOYEES
79
PRICE TARGET
Target High$40.00
Target Low$35.00
Target Median$36.00
Target Consensus$36.75
UPCOMING EARNINGS
DateNov 12, 2026
DayThursday
Rev. Est.$3.81M
NOV
12
THU
PRICE
$27.05 ▲ UP 1.50% (+$0.40)About Aktis Oncology, Inc.
https://www.aktisoncology.com ↗Aktis Oncology, Inc. is a Boston-based clinical-stage company developing targeted radiopharmaceutical therapies, including Nectin-4 and B7-H3 conjugates, for treating various cancers such as urothelial, breast, lung, and colorectal.
INDUSTRY
Biotechnology
A PRODUCT AKTIS ONCOLOGY, INC. IS KNOWN FOR
AKY-1189
AKY-1189, Aktis Oncology's lead targeted alpha radiopharmaceutical in Phase 1b, aims to treat Nectin-4 expressing solid tumors by delivering radioactive payloads directly to cancer cells, minimizing harm to healthy tissue.
ETFS HOLDING THIS STOCK
ETFS HOLDING
67
LISTED HERE
14
RANKED BY POSITION SIZE
INSTITUTIONAL OWNERSHIP
SHARES OWNED
51.70%
HOLDERS
119
TOP 12 OF 119 · RANKED BY POSITION SIZE
Bioimpact Capital LLC
Ecor1 Capital, LLC
Blue Owl Capital Holdings LP
Wellington Management Group Llp
Blackrock, Inc.
T. Rowe Price Investment Management, Inc.
Rtw Investments, LP
Price T Rowe Associates Inc /Md/
Ra Capital Management, L.P.
Janus Henderson Group Plc
Baker Bros. Advisors LP
Octagon Capital Advisors LP
RATINGS SNAPSHOT
Overall rating: C+
Discounted Cash Flow3
Return On Equity1
Return On Assets1
Debt To Equity4
Price To Earnings1
Price To Book2
Overall Score2
INSIDER TRADES
★
10 PERCENT OWNER
ELI LILLY & Co
— · —
2026-01-12
MOST RECENT ANALYST GRADES
GRADE SUMMARY
OVERWEIGHT 1
BUY 1
2 GRADES IN THE LAST 12 MONTHS
